The Galien Foundation Debuts 2021 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent," "Best Medical Technology" and "Best Digital Health Solution" Categories

NEW YORK, July 20, 2021 /PRNewswire/ -- The Galien Foundation today announced the 2021 Prix Galien USA Award nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," "Best Medical Technology" and "Best Digital Health Product." This year's ceremony is the Prix Galien's 50^th, marking half a century of recognizing excellence in biopharmaceutical and medical technology innovations that improve the human condition. Winners will be announced during the Prix Galien USA Awards Ceremony on October 28, 2021 in New York City. The ceremony will adhere to recommendations from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).

"The Awards Committee is excited to introduce the nominees for the 2021 Prix Galien USA Awards. These products have been created by scientists who have dedicated their lives to discovering, developing and distributing life-saving answers for patients," said Dr. Sue Desmond-Hellmann, Chair of the Prix Galien USA and Prix Galien International Award Committees and former CEO of the Bill & Melinda Gates Foundation. "We appreciate the opportunity to honor these researchers and their tireless efforts."

The 2021 Prix Galien USA nominees, totaling a record-breaking 81 product nominations, include products evaluated in the following categories: "Best Biotechnology Product" – 19 nominees; "Best Pharmaceutical Agent" – 34 nominees; "Best Medical Technology" – 18 nominees; and "Best Digital Health Solution" – 10 nominees.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact.

Best Biotechnology Product (Nominees)

Best Pharmaceutical Agent (Nominees)

Best Medical Technology (Nominees)

Best Digital Health Solution (Nominees)

"These nominees reflect our celebration of 50 years of the Prix Galien Awards and the progress made in working to improve the state of human health," said Bruno Cohen, Chairman of The Galien Foundation. "We look forward to honoring these nominees and all of their accomplishments on October 28."

To commemorate the last 50 years of Prix Galien Awards, the Golden Jubilee will honor the "global best of the very best" in A- Pharmaceutical; B- Biotechnology; C- Orphan and Rare diseases; D- Vaccines; and E- Medical technology products. Eligibility will be drawn from close to 300  awarded products selected by our 14 member-country chapters since 1970, developed by more than 80 innovative companies, most of whom continue to bring new therapies for today's patients with unmet medical needs. During the USA Ceremony, the short list for the "Awards of the Jubilee" will be announced. The Golden Jubilee awards will be presented on December 11 in Dakar, Senegal in the presence of the President of the Senegalese Republic, H.E. Macky Sall, alongside many African heads of state and ministers of health and/or environment, WHO Director-General, Tedros Adhanom Ghebreyesus, as well as hundreds of scientists, industry and innovation leaders. Learn more about the 50 years of Prix Galien here.

The Prix Galien USA Awards Committee is composed of twelve renowned leaders from the biomedical industry and academia, including five Nobel Laureates, responsible for evaluating nominees. The Prix Galien USA Digital Health Awards Committee is composed of nine distinguished leaders from the biomedical industry and academia, responsible for evaluating nominees.

Prix Galien Awards Committee 2021

Sue DESMOND-HELLMANN
M.D., M.P.H., Former Chief Executive Officer, Bill & Melinda Gates Foundation
Committee Chair

Richard AXEL
M.D., Nobel Laureate, Co-director, The Kavli Institute for Brain Science; Professor, Columbia University Medical Center

Linda BUCK
Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington

Laurie GLIMCHER
M.D., President and CEO, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Mary-Claire KING
Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington

Robert S. LANGER
M.D., David H. Koch Institute Professor, Massachusetts Institute of Technology

Cato T. LAURENCIN
M.D., Ph.D. University Professor, University of Connecticut

Steven J. LESTER
M.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator

Michael ROSENBLATT
M.D., Chief Medical Officer, Flagship Pioneering

Bengt SAMUELSSON
M.D., Ph.D., Nobel Laureate; Professor Karolinska Institutet; Former President, Karolinska institute; Former Chairman, Nobel Foundation

Marc TESSIER-LAVIGNE
Ph.D., President, Stanford University

Tachi YAMADA
M.D., Venture Partner, Frazier Healthcare Partners

Elie WIESEL
Nobel Peace Prize Laureate, Boston University, Honorary Founding President, In Memoriam

Prix Galien Digital Health Award Committee 2021

Bernard POUSSOT,
Director, Roche Holding, Former Chairman & CEO, Wyeth
Committee chair

Roch DOLIVEUX,
Honorary CEO, UCB

Mikael DOLSTEN,
Global R&D President, Pfizer

Jean-Pierre GARNIER,
Former CEO, GSK

Penny HEATON
CEO, Bill & Melinda Gates Medical Research Institute

Franz HUMER
Former CEO, Roche

François MAISONROUGE,
Senior Managing Director, Evercore Partners

Sheri MCCOY
Former CEO, Avon Products
Former Vice-Chairman, Johnson & Johnson

Elias ZERHOUNI,
Former Global Head of R&D, Sanofi

About the Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health.  Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. 

The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.  The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Related Links

http://www.galienfoundation.org

SOURCE The Galien Foundation